Cargando…

HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer

Endocrine-therapy-resistant estrogen receptor–positive (ER+) breast cancer cells often exhibit an augmented capacity to maintain endoplasmic reticulum (EnR) homeostasis under adverse conditions. Oncoprotein hepatitis B X-interacting protein (HBXIP) is a known transcriptional coactivator that promote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shenghong, Wang, Ranran, Wang, Xinyue, Guo, Xueling, Du, Yanyan, Guo, Xin, Zong, Xinlan, Zhu, Changhui, Zhou, Xiaolei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908272/ https://www.ncbi.nlm.nih.gov/pubmed/35093383 http://dx.doi.org/10.1016/j.jbc.2022.101644

Ejemplares similares

HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
por: Liu, Bowen, et al.
Publicado: (2018)

HBXIP blocks myosin-IIA assembly by phosphorylating and interacting with NMHC-IIA in breast cancer metastasis
por: Zhang, Lu, et al.
Publicado: (2023)

MiR‐145‐targeted HBXIP modulates human breast cancer cell proliferation
por: Jiang, Yang, et al.
Publicado: (2018)

Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth
por: Jiang, Yang, et al.
Publicado: (2018)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer
por: Wang, Yixuan, et al.
Publicado: (2017)

Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer
por: Chen, Rui, et al.
Publicado: (2020)

The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer
por: Liu, Fabao, et al.
Publicado: (2015)

The oncoprotein HBXIP facilitates metastasis of hepatocellular carcinoma cells by activation of MMP15 expression
por: Zheng, Sen, et al.
Publicado: (2019)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients
por: Ruan, Lingjuan, et al.
Publicado: (2018)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
por: Ma, Ji, et al.
Publicado: (2014)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)

HBXIP activates the PPARδ/NF-κB feedback loop resulting in cell proliferation
por: Liu, Qian, et al.
Publicado: (2017)

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
por: Zheng, XQ, et al.
Publicado: (2013)

δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer
por: Guo, Shaocong, et al.
Publicado: (2012)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model
por: De Oliveira Andrade, Fabia, et al.
Publicado: (2019)

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells
por: Yue, Lin, et al.
Publicado: (2013)

Virus-induced ER stress and the unfolded protein response
por: Zhang, Lingrui, et al.
Publicado: (2012)

Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells
por: Qi, Wenwen, et al.
Publicado: (2016)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
por: Lu, Renquan, et al.
Publicado: (2016)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
por: Li, Ying, et al.
Publicado: (2020)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Xue, Xingyang, et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

HBXIP Regulates Gastric Cancer Glucose Metabolism and Malignancy Through PI3K/AKT and p53 Signaling
por: Qiu, Lei, et al.
Publicado: (2020)

Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP
por: Zhang, Weiying, et al.
Publicado: (2014)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gft1hd15j61dr3lhufsubdccs3